Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies

Natsumi Kawasaki(Chugai Pharma (United States)), Yasushi Yoshimura
Molecular Biology Reports
February 26, 2022
Cited by 11


Related Papers